JAPZO Rec'd PST/PID 03 AUG 2006

Attorney Docket No.: 10582.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duffner et al.

Confirmation No: To be assigned

Serial No.: TBA

Group Art Unit: To be assigned

Filed: August 03, 2006

Examiner: To be assigned

For: Xylanase

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: August 03, 2006

Jasop I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212)840-0097

MYZO Rec'd PCT/PTO 0 3 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid-OMB control-number. Complete if Known / 988670 Substitute for form 1449A/PTO **Application Number** TBA INFORMATION DISCLOSURE Filing Date August 03, 2006 First Named Inventor STATEMENT BY APPLICANT Duffner et al. **Art Unit** (use as many sheets as necessary) To be assigned **Examiner Name** To be assigned Sheet **Attorney Docket Number** of 10582.204-US

	U.S PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US 20040028773	02-12-2004	Sturkenboon et al			
							
	+						
	l						

		FOREIGN F	ATENT DOCU	MENTS		
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code 3 – Number 4 – Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т 6
		WO 03/106654	12-24-2003	Versa Corp		
		WO 00/39289	07-06-2000	Danisco		
		WO 96/32472	10-17-1996	Novo Nordisk		
		WO 95/23515	09-08-1995	Novo Nordisk		
	<u> </u>					
	├					
	 -					
	$\overline{}$					
	ļ					
	ļ					
	 					
	 					· · ·
	 					
	 		· · · · · · · · · · · · · · · · · · ·			
	 				-	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

iAP20 Rec'd PCT/PTO 03 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction Ad	ct of 1995, no perso	ons are required to re	spond to a conection of internation unle	ss it contains a valid Oivib control number.
Substitute fo	r form 1449A/PTO			Сотр	lete if Known
				Application Number	4 TBA/ E 00 2 0 0
	INFORMATION	ON DISCLOSI	URE	Filing Date	1 Magus 23 2006 7 0
	STATEMENT	BY APPLICA	ANT	First Named Inventor	Duffner et al.
	(use as many	sheets as necessar	ny)	Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2.	of	2	Attorney Docket Number	10582.204-US

		OTHER REION ART. MON PATENT HERRATHER ROOMERIES	
	1 00	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		EMBL-EBI, Accession # D32065, (1994)	
		EMBL-EBI, Accession # AF195421, (2000)	
·		Kubata et al, Bio Science Biotech, Biochemistry, Vol. 56, Part 9, pages 1463-1464 (1992)	-
	1		
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.